Numeta G16% E (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Numeta G16% E is used as a component of parenteral nutrition regimens for patients with increased protein and amino acid requirements.

• Critical care patients: provides essential amino acids to support catabolic stress response.
• Neonates and preterm infants: supplies balanced amino acid profile for growth and development.
• Post‑surgical patients: aids in protein synthesis during recovery.
• Patients with malabsorption syndromes: delivers nutrition when enteral feeding is insufficient.
• Long‑term home parenteral nutrition: maintains nutritional status over extended periods.

• Numeta G16% E delivers a balanced mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing the gastrointestinal tract. The amino acids serve as substrates for protein synthesis, support nitrogen balance, and contribute to the production of neurotransmitters and metabolic intermediates, thereby meeting the heightened metabolic demands of critically ill or growing patients.

Numeta G16% E may be associated with infusion‑related reactions and metabolic disturbances.

Common Side Effects

• Hyperglycaemia: elevated blood glucose levels during infusion.
• Electrolyte imbalance: changes in potassium, sodium or calcium concentrations.
• Mild fever or chills: transient temperature rise during administration.
• Local irritation: redness or discomfort at the infusion site.
• Nausea: occasional sensation of queasiness.
• Headache: mild headache reported by some patients.

Serious or Rare Side Effects

• Anaphylactic reaction: severe allergic response requiring immediate medical intervention.
• Metabolic acidosis: significant drop in blood pH due to amino acid metabolism.
• Hyperosmolarity: increased serum osmolarity leading to fluid shifts.
• Thrombophlebitis: inflammation of the vein with clot formation.
• Sepsis: infection risk if aseptic technique is compromised.
• Renal impairment: worsening kidney function in susceptible individuals.

When using Numeta G16% E, clinicians should assess patient-specific factors and monitor relevant parameters.

• Assess renal function: evaluate baseline creatinine and adjust infusion rate if needed.
• Monitor blood glucose: check glucose levels regularly during therapy.
• Check electrolytes: maintain potassium, sodium and calcium within target ranges.
• Observe infusion site: watch for signs of phlebitis or infiltration.
• Review hepatic function: consider liver enzyme trends in long‑term use.
• Store at ambient temperature: keep in original container, protect from moisture and direct sunlight.

Numeta G16% E can interact with other intravenously administered agents, influencing metabolic balance and infusion compatibility.

Major Interactions (Avoid)

• Incompatible solutions: avoid mixing with calcium‑containing solutions that may precipitate.
• High‑dose insulin: concurrent use may exacerbate hypoglycaemia.

Moderate Interactions (Monitor Closely)

• Diuretics: may increase electrolyte loss, requiring closer monitoring.
• Corticosteroids: can augment protein catabolism, affecting amino‑acid requirements.
• Parenteral lipid emulsions: combined regimens need careful osmolarity assessment.
• Anticoagulants: monitor clotting parameters if central venous access is used.
• Vasopressors: may alter peripheral circulation affecting infusion tolerance.